Pharmafile Logo
Pharmafocus logo
Advanced Search

Vidaza

Showing 5 posts of 5 posts found.

celgene_1_02

Nice rejects Celgene’s drug to treat blood cancer

June 24, 2016
Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer

The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …

News
Vidaza product image

Celgene’s Vidaza earns wider approval

November 2, 2015
Sales and Marketing Celgene, European Commission, Vidaza, acute myeloid leukaemia, azacitidine, leukaemia

Swiss firm Celgene has been given approval by the European Commission to extend its marketing authorisation for the cancer treatment …

News

Vidaza patient access scheme sways NICE

February 17, 2011
Sales and Marketing Celgene, NICE, Vidaza

Celgene’s Vidaza has been recommended by NICE in final draft guidance issued today. Vidaza (azacitidine) is recommended as a treatment …

News

Vidaza too costly for NICE

March 8, 2010
Sales and Marketing Celgene, NICE, Vidaza

NICE has rejected Celgene’s Vidaza for use on the NHS to treat the rare bone marrow disease myelodysplastic syndrome. The …

News

First-in-class cancer treatment Vidaza launched

March 3, 2009
Research and Development Vidaza

Vidaza, an innovative new treatment for a number of hard-to-treat blood cancers, has been launched in the UK by Celgene. …

News
The Gateway to Local Adoption Series

Latest content

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026